Genomic characterization for familial cases with urothelial carcinoma
- 12 Downloads
In this report, we present familial cases of urothelial carcinoma. To investigate the possibility of hereditary urothelial cancer, we performed semiconductor-based next-generation DNA sequencing. A woman in her 80s who had bladder and left ureteral cancer was hospitalized in Sapporo Shirakaba-dai Hospital due to consciousness disturbance. Radiographic evaluation revealed multiple liver metastases and she died 38 days later. Needle necropsy was done for a left ureteral tumor that continued to her bladder tumor and for liver metastases. At the same time, her son in his 60s, who also had muscle-invasive bladder cancer, was admitted to Sapporo Medical University Hospital and underwent neoadjuvant chemotherapy followed by laparoscopic radical cystectomy. DNA was isolated from both cancers and normal controls in each case and analyzed by massive parallel sequencing of 409 cancer-related genes using a targeted, multiplex PCR approach followed by semiconductor sequencing. Somatic mutations of KMT2C and KMT2D were detected in the mother’s tumor. Copy number gains of FGFR1, IkBKB, NFkB2, FGFR2, and FLT3 and copy number losses of IGF2R and TP53 were also found in her cancer. In her son’s tumor, somatic mutations of FGFR3 and EP300 were identified. Copy number gains of IkBKE/MAPK1/PARP1, EGFR, BRAF, IRS2, MAPK2K1, IGF1R, and ERBB2 and copy number loss of TP53 were also found in his cancer. There were no germline gene mutations related to familial urothelial carcinoma. Although somatic mutation of TP53 was a common feature, these cases with urothelial carcinoma might not be the result of a heredity syndrome.
KeywordsUrothelial cancer Familial cancer Next-generation sequencing
Non-muscle-invasive bladder cancer
Muscle-invasive bladder cancer
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflict of interest.
Written informed consent was obtained from the patients.
- 9.Nakagaki T, Tamura M, Kobashi K, Omori A, Koyama R, Idogawa M, Ogi K, Hiratsuka H, Tokino T, Sasaki Y (2018) Targeted next-generation sequencing of 50 cancer-related genes in Japanese patients with oral squamous cell carcinoma. Tumour Biol 40(9):1010428318800180. https://doi.org/10.1177/1010428318800180 CrossRefGoogle Scholar
- 10.Nakagaki T, Tamura M, Kobashi K, Koyama R, Fukushima H, Ohashi T, Idogawa M, Ogi K, Hiratsuka H, Tokino T, Sasaki Y (2017) Profiling cancer-related gene mutations in oral squamous cell carcinoma from Japanese patients by targeted amplicon sequencing. Oncotarget 15(35):59113–59122. https://doi.org/10.18632/oncotarget.19262 Google Scholar
- 12.Van der Post RS, Kiemeney LA, Ligtenberg MJL, Witjes JA, Hulsbergen-van de Kaa CA, Bodmer D, Schaap L, Kets CM, van Krieken JH, Hoogerbrugge N (2010) Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among msh2 mutation carriers. J Med Genet 47:464–470CrossRefGoogle Scholar
- 13.Hollande C, Colin P, de La Motte Rouge T, Audenet F, Yates DR, Phé V, Ouzzane A, Droupy S, Ruffion A, de La Taille A, Guy L, Cussenot O, Rozet F, Xylinas E, Zerbib M, Spano JP, Khayat D, Bitker MO, Rouprêt M (2014) Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours. BJU Int 113:574–580CrossRefGoogle Scholar
- 14.Sung JY, Sun JM, Chang Jeong B, Seo S, Soo Jeon S, Moo Lee H, Yong Choi H, Young Kang S, Choi YL, Young Kwon G (2014) FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy. Urol Oncol 1:e23–e31Google Scholar
- 15.Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW (2016) Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. Ann Oncol 7:1311–1316CrossRefGoogle Scholar
- 17.Olanoa AR, Bellmunta J, Rodrigob A, Álvarezb L, Terrádezb A, García-Foncillasb J, Laesc JF (2017) A case report demonstrating the potential clinical benefit of exhaustive molecular profiling in an aggressive muscle-invasive high-grade metastatic urothelial carcinoma. Case Rep Oncol. https://doi.org/10.1159/000477337 Google Scholar
- 18.Wei L, Youquan W, Shubo T, Qishuo R, Tian Z, Guo H, Zhuo L, Guowen L (2018) Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in bladder carcinoma and its association with patients’ clinical features. Med Sci Monit 24:7178–7185. https://doi.org/10.12659/MSM.911640 CrossRefGoogle Scholar